Detalles de la búsqueda
1.
CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.
Mol Cell Biochem
; 356(1-2): 45-50, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21735096
2.
Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial.
ACS Pharmacol Transl Sci
; 4(1): 206-212, 2021 Feb 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33615173
3.
Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.
BMC Cancer
; 9: 146, 2009 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-19439079
4.
Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac.
Front Oncol
; 9: 49, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30859088
5.
CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation.
Semin Oncol
; 45(1-2): 58-67, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30318085
6.
Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial.
ISRN Obstet Gynecol
; 2011: 292951, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21748025
7.
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
Mol Cell Biochem
; 316(1-2): 163-7, 2008 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-18575815
8.
Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial
ISRN Obstet Gynecol
; 20112011.
Artículo
en Inglés
| CUMED | ID: cum-60373
9.
Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies
BMC Cancer
; 9May 13, 2009. tab
Artículo
en Inglés
| CUMED | ID: cum-39785
Resultados
1 -
9
de 9
1
Próxima >
>>